Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after ...

Higher costs and issues with Russia led Vertex Pharmaceuticals to miss profit and sales estimates. Constellation Energy beat revenue forecasts and reiterated its full-year earnings guidance on ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) have been very resilient in the last six months. There was that brief trip to just below $400 per share in December after suzetrigine (Journavx ...

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported first-quarter results that fell short of analyst expectations, sending shares down 2.8% in after-hours trading on Monday.

Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. This biotech stock should still generate exceptional returns over the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...